Article Review: Coloration Biochemistry and Molecular Biology Between Polycystic Ovary Syndrome and Diabetes Mellitus Type 2

  • Noora Wael Rasheed Al-Rafidain University College, IRAQ
  • Abeer Ali Marhoon Al-Rafidain University College, IRAQ
Keywords: T2DM, PCOS, Genes, Type 2 Diabetes


Polycystic ovarian syndrome is the most common reproductive endocrine disorder in premenopausal women Given the clinical overlap between PCOS and type 2 diabetes mellitus (T2DM), this research sought to investigate if genes associated with T2DM were similarly connected to PCOS vulnerability. In either the univariate or multivariate scenario, none of the 16 SNPs was significantly associated with Polycystic Ovarian Syndrome after Bonferroni correction for multiple testing. The nine T2DM genes investigated in this preliminary research may not be the main PCOS risk factors in Indian women. Our findings add to the absence of evidence of a link between T2DM genes and PCOS in Chinese and Caucasians, suggesting that this trend may be universal. To determine the exact significance of the diabetes genes, researchers will need to conduct extensive studies that involve women with T2DM and PCOS.


Download data is not yet available.


Dasgupta S, Reddy BM. Present status of understanding on the genetic etiology of polycystic ovary syndrome. J Postgrad Med. 2008;54:115–25.

Welt CK, Duran JM. Genetics of polycystic ovary syndrome. Semin Reprod Med. 2014;32:177–82.

Shaikh N, Roshan D, Mukherjee S. Genetic markers of polycystic ovary syndrome: emphasis on insulin resistance. Int J Med Genet 2014. 2014:10.

Goodarzi MO, Louwers YV, Taylor KD, Jones MR, Cui J, Kwon S, et al. Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil Steril. 2011;95:1736–41.e1-11.

Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update. 2001;7:405–10.

El Mkadem SA, Lautier C, Macari F, Molinari N, Lefèbvre P, Renard E, et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes. 2001;50:2164–8.

Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S, et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:2606–10.

Ruan Y, Ma J, Xie X. Association of IRS-1 and IRS-2 genes polymorphisms with polycystic ovary syndrome: a meta-analysis. Endocr J. 2012;59:601–9.

Shen W, Li T, Hu Y, Liu H, Song M. Calpain-10 genetic polymorphisms and polycystic ovary syndrome risk: a meta-analysis and meta-regression. Gene. 2013;531:426–34.

San-Millán JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence. Clin Endocrinol (Oxf) 2010;72:383–92.

Kim JJ, Choi YM, Cho YM, Hong MA, Chae SJ, Hwang KR, et al. PCOS is not associated with polymorphisms of the TCF7L2, CDKAL1, HHEX, KCNJ11, FTO and SLC30A8 genes. Clin Endocrinol (Oxf) 2012;77:439–45.

Saxena R, Welt CK. PCOS is not associated with genetic variants that mark risk of type 2 diabetes. Acta Diabetol. 2013;50:451–7.

Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, et al. Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. Fertil Steril. 2011;95:2538–41.e1-6.

Abate N, Chandalia M. Ethnicity, type 2 diabetes and migrant Asian Indians. Indian J Med Res. 2007;125:251–8.

Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217–30.

Sundararaman PG, Manomani R, Sridhar GR, Sridhar V, Sundaravalli A, Umachander M. Risk of atherosclerosis in women with polycystic ovary syndrome: a study from South India. Metab Syndr Relat Disord. 2003;1:271–5.

Kommoju UJ, Reddy BM. Genetic etiology of type 2 diabetes mellitus: a review. Int J Diabetes Dev Ctries. 2011;31:51–64.

Tabassum R, Chauhan G, Dwivedi OP, Mahajan A, Jaiswal A, Kaur I, et al. Genome-wide association study for type 2 diabetes in Indians identifies a new susceptibility locus at 2q21. Diabetes. 2013;62:977–86.

Saxena R, Saleheen D, Been LF, Garavito ML, Braun T, Bjonnes A, et al. Genome-wide association study identifies a novel locus contributing to type 2 diabetes susceptibility in Sikhs of Punjabi origin from India. Diabetes. 2013;62:1746–55.

Uma Jyothi K, Reddy BM. Gene-gene and gene-environment interactions in the etiology of type 2 diabetes mellitus in the population of Hyderabad, India. Meta Gene. 2015;5:9–20.

Dasgupta S, Sirisha P, Neelaveni K, Anuradha K, Sudhakar G, Reddy BM. Polymorphisms in the IRS-1 and PPAR-γ genes and their association with polycystic ovary syndrome among South Indian women. Gene. 2012;503:140–6.

Dasgupta S, Sirisha PV, Neelaveni K, Anuradha K, Reddy BM. Association of CAPN10 SNPs and haplotypes with polycystic ovary syndrome among South Indian Women. PLoS One. 2012;7:e32192.

Shaikh N, Mukherjee A, Shah N, Meherji P, Mukherjee S. Peroxisome proliferator activated receptor gamma gene variants influence susceptibility and insulin related traits in Indian women with polycystic ovary syndrome. J Assist Reprod Genet. 2013;30:913–21.

Dasgupta S, Reddy BM. The role of epistasis in the etiology of polycystic ovary syndrome among Indian women: SNP-SNP and SNP-environment interactions. Ann Hum Genet. 2013;77:288–98.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.

Sambrook J, Fritschi EF, Maniatis T. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press; 1989.

Biyasheva A, Legro RS, Dunaif A, Urbanek M. Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. J Clin Endocrinol Metab. 2009;94:2617–25.

Ewens KG, Jones MR, Ankener W, Stewart DR, Urbanek M, Dunaif A, et al. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One. 2011;6:e16390.

Xu P, Che Y, Cao Y, Wu X, Sun H, Liang F, et al. Polymorphisms of TCF7L2 and HHEX genes in Chinese women with polycystic ovary syndrome. J Assist Reprod Genet. 2010;27:23–8.

Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care. 2001;24:1050–2.

Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, et al. PCOS is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes. 2012;61:2369–74.

Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, et al. PCOS, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reprod Med 2014. 2014:719050.

Barber TM, Franks S. The link between polycystic ovary syndrome and both type 1 and type 2 diabetes mellitus: what do we know today? Women's Health (Lond) 2012;8:147–54.

B. Pintaudi, G. Di Vieste, and M. Bonomo, "The effectiveness of myo-inositol and D-chiro inositol treatment in type 2 diabetes," International Journal of Endocrinology, vol. 2016, Article ID 9132052, 5 pages, 2016.

V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, "Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials," Gynecological En- docrinology, vol. 28, no. 7, pp. 509–515, 2012.

V. Unfer, F. Facchinetti, B. Orru`, B. Giordani, and J. Nestler, "Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials," Endocrine Connections, vol. 6, no. 8, pp. 647–658, 2017.

J. Pundir, D. Psaroudakis, P. Savnur et al., "Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomized trials," BJOG: An International Journal of Obstetrics & Gynaecology, vol. 125, no. 3, pp. 299–308, 2018.

N. Galazis, M. Galazi, and W. Atiomo, "D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review," Gynecological Endocrinology, vol. 27, no. 4, pp. 256–262, 2011.

L. Zeng and K. Yang, "Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta- analysis," Endocrine, vol. 59, no. 1, pp. 30–38, 2018.

F. Facchinetti, B. Orru`, G. Grandi, and V. Unfer, "Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials," Gynecological Endocrinology, vol. 35, no. 3, pp. 198–206, 2019.

F. Facchinetti, M. Appetecchia, C. Aragona et al., "Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond," Expert Opinion on Drug Metabolism & Toxicology, vol. 16, no. 3, pp. 255–274, 2020.

V. Lubin, R. Shojai, P. Darmon, and E. Cosson, "A pilot study of gestational diabetes mellitus not controlled by diet alone: first-line medical treatment with myoinositol may limit the need for insulin," Diabetes & Metabolism, vol. 42, no. 3, pp. 192–195, 2016.

F. Fraticelli, C. Celentano, I. A. Zecca et al., "Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial," Acta Dia- betologica, vol. 55, no. 8, pp. 805–812, 2018.

C. Celentano, B. Matarrelli, G. Pavone et al., "The influence of different inositol stereoisomers supplementation in preg- nancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial," The Journal of Maternal-Fetal & Neonatal Medicine, vol. 33, no. 5, pp. 743–751, 2020.

A. Vitagliano, G. Saccone, E. Cosmi et al., "Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials," Archives of Gynecology and Obstetrics, vol. 299, no. 1, pp. 55–68, 2019.

X. Tan, S. Li, Y. Chang et al., "Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis," Clinical & Investigative Medicine, vol. 39, no. 4, pp. E120–E131, 2016.

J. Zhao, X. Liu, and W. Zhang, "The effect of metformin therapy for preventing gestational diabetes mellitus in women with polycystic ovary syndrome: a meta-analysis," Experi- mental and Clinical Endocrinology & Diabetes, vol. 128, no. 3, pp. 199–205, 2018.

Z. Zhuo, A. Wang, and H. Yu, "Effect of metformin inter- vention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic re- view and meta-analysis," Journal of Diabetes Research, vol. 2014, Article ID 381231, 13 pages, 2014.

R. Bidhendi Yarandi, S. Behboudi-Gandevani, M. Amiri, and F. R. Tehrani, "Metformin therapy before conception versus throughout the pregnancy and risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systemic review, meta-analysis and meta-regression," Diabetology & Metabolic Syndrome, vol. 11, no. 1, p. 58, 2019.

Q. Du, S. Yang, Y.-J. Wang, B. Wu, Y.-Y. Zhao, and B. Fan, "Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials," Ad- vances in Therapy, vol. 29, no. 9, pp. 763–774, 2012.

Q. Du, Y.-J. Wang, S. Yang, B. Wu, P. Han, and Y.-Y. Zhao, "A systematic review and meta-analysis of randomized con- trolled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome," Current Medical Research and Opinion, vol. 28, no. 5, pp. 723–730, 2012.

V. R. Aroda, T. P. Ciaraldi, P. Burke et al., "Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial," The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 2, pp. 469–476, 2009.

X.-J. Li, Y.-X. Yu, C.-Q. Liu et al., "Metformin vs thiazoli- dinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis," Clinical Endocrinology, vol. 74, no. 3, pp. 332–339, 2011.

Z. Javed, M. Papageorgiou, H. Deshmukh et al., "Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study," Clinical Endo- crinology, vol. 90, no. 6, pp. 805–813, 2019.

M. Jensterle, N. Aleksandra Kravos, K. Goricˇar, and A. Janez, "Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial," BMC Endocrine Disorders, vol. 17, no. 1, p. 5, 2017.

H. Teede, E. C. Tassone, T. Piltonen et al., "Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: a systematic re- view with meta-analyses," Clinical Endocrinology, vol. 91, no. 4, pp. 479–489, 2019.

G. Conway, D. Dewailly, E. Diamanti-Kandarakis et al., "European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire," European Journal of Endo- crinology, vol. 171, no. 4, pp. 489–498, 2014.

Tang, J. M Lord, R. J. Norman, E. Yasmin, and A. H. Balen, "Insulin-sensitizing drugs (metformin, rosiglitazone, piogli- tazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility," The Cochrane Database of Systematic Reviews, vol. 5, Article ID CD003053, 2012.

R. Patel and G. Shah, "Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials," Current Medical Research and Opinion, vol. 33, no. 9, pp. 1545–1557, 2017

L. J. McCreight, C. J. Bailey, and E. R. Pearson, "Metformin and the gastrointestinal tract," Diabetologia, vol. 59, no. 3, pp. 426–435, 2016.

C. L. Harrison, N. K. Stepto, S. K. Hutchison, and H. J. Teede, "The impact of intensified exercise training on insulin re- sistance and fitness in overweight and obese women with and without polycystic ovary syndrome," Clinical Endocrinology, vol. 76, no. 3, pp. 351–357, 2012.

I. Almenning, A. Rieber-Mohn, K. M. Lundgren, T. S. Løvvik, K. K. Garnæs, and T. Moholdt, "Effects of high intensity interval training and strength training on metabolic, car- diovascular and hormonal outcomes in women with poly- cystic ovary syndrome: a pilot study," PLoS One, vol. 10, no. 9, Article ID e0138793, 2015.

M. Cree-Green, H. Rahat, B. R. Newcomer et al., "Insulin resistance, hyperinsulinemia, and mitochondria dysfunction in non-obese girls with polycystic ovarian syndrome," Journal of the Endocrine Society, vol. 1, no. 7, pp. 931–944, 2017.

L. Lindheim, M. Bashir, J. Mu¨nzker et al., "Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): a pilot study," PLoS One, vol. 12, no. 1, Article ID e0168390, 2017.

L. Moran, G. Brinkworth, and R. Norman, "Dietary therapy in polycystic ovary syndrome," Seminars in Reproductive Med- icine, vol. 26, no. 1, pp. 085–092, 2008.

A. Neven, J. Laven, H. Teede, and J. Boyle, "A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines," Seminars in Reproductive Medicine, vol. 36, no. 1, pp. 005–012, 2018.

Z. Faghfoori, S. Fazelian, M. Shadnoush, and R. Goodarzi, "Nutritional management in women with polycystic ovary syndrome: a review study," Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 11, no. Suppl 1, pp. S429– S432, 2017.

J. P. Domecq, G. Prutsky, R. J. Mullan et al., "Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis," The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 12, pp. 4655–4663,2013.

H. J. Teede, M. L. Misso, M. F. Costello et al., "Recommen- dations from the international evidence-based guideline for the assessment and management of polycystic ovary syn- drome," Fertility and Sterility, vol. 110, no. 3, pp. 364–379, 2018.

A. L. C. Torchen, N. R. Fogel, W. J. Brickman, R. Paparodis, and Dunaif, "Persistent apparent pancreatic β-cell defects in premenarchal PCOS relatives," The Journal of Clinical En- docrinology & Metabolism, vol. 99, no. 10, pp. 3855–3862, 2014.

F. R. Day, D. A. Hinds, J. Y. Tung et al., "Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome," Nature Communications, vol. 6, no. 1, p. 8464, 2015.

L. C. Torchen, "Cardiometabolic risk in PCOS: more than a reproductive disorder," Current Diabetes Reports, vol. 17, no. 12, p. 137, 2017.

E. Diamanti-Kandarakis and A. Dunaif, "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications," Endocrine Reviews, vol. 33, no. 6, pp. 981–1030, 2012.

D. A. Dumesic, S. E. Oberfield, E. Stener-Victorin, J. C. Marshall, J. S. Laven, and R. S. Legro, "Scientific state- ment on the diagnostic criteria, epidemiology, pathophysi- ology, and molecular genetics of polycystic ovary syndrome," Endocrine Reviews, vol. 36, no. 5, pp. 487–525, 2015.

International Diabetes Federation, Idf Diabetes Atlas, Inter- national Diabetes Federation, Brussels, Belgium, 8 edition, 2017.

A. J. Goverde, A. J. van Koert, M. J. Eijkemans et al., "In- dicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria," Human Reproduction (Oxford, England), vol. 24, no. 3, pp. 710–717, 2009.”

How to Cite
Noora Wael Rasheed, & Abeer Ali Marhoon. (2021). Article Review: Coloration Biochemistry and Molecular Biology Between Polycystic Ovary Syndrome and Diabetes Mellitus Type 2. International Journal for Research in Applied Sciences and Biotechnology, 8(4), 117-123.